TfR targeting was recently used also to deliver theranostic agents [110] and to modify liposomal nanoparticles in combination with p-aminophenyl-α-d-manno-pyranoside, targeting GLUT-1 to achieve a double targeting of BBB and cancer cells [111]. The gene discussed is TFRC; the disease is cancer.